282: Lilly’s obesity drug, the power of radiation, & a biotech implosion

This podcast explores the scientific backstory of radiopharmaceuticals, Eli Lilly's new obesity drug, a biotech implosion, and shareholder activism. They also discuss the approval and pricing of Lilly's weight loss drug, upcoming cardiovascular outcome study for Novo Nordisk's WeGoV, and updates in the pharmaceutical industry. Additionally, they delve into the history of the radiopharmaceutical Zevelin and a bittersweet day for IDEC and Zevelin employees during an FDA advisory panel meeting.